See more : Baumart Holdings Limited (BMH.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Fulgent Genetics, Inc. (FLGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fulgent Genetics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Lonza Group AG (LZAGF) Income Statement Analysis – Financial Results
- AEye, Inc. (LIDRW) Income Statement Analysis – Financial Results
- NovelStem International Corp. (NSTM) Income Statement Analysis – Financial Results
- WedoTalk Inc. (SHNL) Income Statement Analysis – Financial Results
- Prosperity International Holdings (H.K.) Limited (0803.HK) Income Statement Analysis – Financial Results
Fulgent Genetics, Inc. (FLGT)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.fulgentgenetics.com
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2001 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 289.21M | 618.97M | 992.58M | 421.71M | 32.53M | 21.36M | 18.73M | 18.28M | 9.58M | 1.28M | 0.00 |
Cost of Revenue | 184.76M | 252.07M | 215.53M | 89.81M | 14.11M | 10.69M | 8.55M | 6.72M | 5.07M | 936.00K | 0.00 |
Gross Profit | 104.46M | 366.90M | 777.05M | 331.91M | 18.42M | 10.67M | 10.18M | 11.56M | 4.51M | 342.00K | 0.00 |
Gross Profit Ratio | 36.12% | 59.28% | 78.29% | 78.70% | 56.63% | 49.94% | 54.35% | 63.22% | 47.07% | 26.76% | 0.00% |
Research & Development | 41.44M | 28.91M | 24.22M | 11.58M | 6.54M | 5.53M | 4.22M | 3.56M | 4.43M | 521.00K | 0.00 |
General & Administrative | 89.00M | 111.07M | 50.73M | 15.22M | 6.41M | 5.54M | 5.13M | 4.61M | 2.42M | 230.00K | 0.00 |
Selling & Marketing | 41.47M | 38.92M | 24.44M | 14.95M | 5.90M | 4.65M | 4.22M | 2.47M | 2.67M | 581.00K | 0.00 |
SG&A | 130.47M | 149.99M | 75.17M | 30.17M | 12.31M | 10.19M | 9.36M | 7.08M | 5.09M | 811.00K | 0.00 |
Other Expenses | 0.00 | 6.50M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.34M |
Operating Expenses | 171.91M | 185.40M | 101.10M | 41.75M | 18.85M | 15.72M | 13.58M | 10.64M | 9.52M | 1.33M | 104.34M |
Cost & Expenses | 364.51M | 437.47M | 316.63M | 131.55M | 32.96M | 26.41M | 22.13M | 17.36M | 14.59M | 2.27M | 104.34M |
Interest Income | 21.44M | 5.50M | 1.35M | 1.53M | 837.00K | 434.00K | 481.00K | 1.00K | 27.00K | 0.00 | 0.00 |
Interest Expense | 0.00 | 5.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.39M | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 26.14M | 36.91M | 12.16M | 3.37M | 2.52M | 2.16M | 1.73M | 1.17M | 575.00K | 196.00K | 0.00 |
EBITDA | -46.55M | 221.59M | 675.95M | 290.16M | 1.68M | -2.91M | -1.75M | 2.09M | -4.44M | -794.00K | 104.34M |
EBITDA Ratio | -16.10% | 30.85% | 68.27% | 68.80% | -1.32% | -23.68% | -18.15% | 5.03% | -46.33% | -62.13% | 0.00% |
Operating Income | -72.70M | 178.53M | 675.95M | 290.16M | -428.00K | -5.06M | -3.40M | 919.00K | -5.01M | -990.00K | 104.34M |
Operating Income Ratio | -25.14% | 28.84% | 68.10% | 68.80% | -1.32% | -23.68% | -18.15% | 5.03% | -52.34% | -77.46% | 0.00% |
Total Other Income/Expenses | -101.39M | 5.50M | 1.35M | 1.53M | 837.00K | 434.00K | 481.00K | -5.39M | 27.00K | 0.00 | 0.00 |
Income Before Tax | -174.09M | 184.03M | 677.30M | 291.68M | 409.00K | -4.62M | -2.92M | -4.47M | -4.99M | -990.00K | 104.34M |
Income Before Tax Ratio | -60.19% | 29.73% | 68.24% | 69.17% | 1.26% | -21.65% | -15.58% | -24.45% | -52.06% | -77.46% | 0.00% |
Income Tax Expense | 1.15M | 42.10M | 174.80M | 72.53M | 43.00K | -1.07M | -768.00K | 920.00K | 3.33M | 3.29M | 0.00 |
Net Income | -167.83M | 143.40M | 507.36M | 214.31M | 366.00K | -4.49M | -2.66M | -5.39M | -8.31M | -4.28M | 104.34M |
Net Income Ratio | -58.03% | 23.17% | 51.12% | 50.82% | 1.13% | -21.02% | -14.21% | -29.48% | -86.82% | -335.13% | 0.00% |
EPS | -5.63 | 4.76 | 17.13 | 9.64 | 0.02 | -0.25 | -0.15 | -0.30 | -0.65 | -0.34 | 3.48 |
EPS Diluted | -5.63 | 4.63 | 16.26 | 9.09 | 0.02 | -0.25 | -0.15 | -0.30 | -0.65 | -0.34 | 3.34 |
Weighted Avg Shares Out | 29.78M | 30.10M | 29.41M | 22.69M | 18.71M | 17.98M | 17.74M | 17.68M | 12.77M | 12.77M | 29.96M |
Weighted Avg Shares Out (Dil) | 29.78M | 30.96M | 30.98M | 24.06M | 18.71M | 17.98M | 17.74M | 17.68M | 12.77M | 12.77M | 31.20M |
FLGT Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Fulgent Genetics, Inc. of Deadline in Securities Fraud Class Action Lawsuit
Fulgent Genetics to Announce Third Quarter 2022 Financial Results on Monday November 7, 2022
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Fulgent Genetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FLGT
After 3rd-Quarter Carnage, Look at the Casualty List
Why I Bought More of This Under-the-Radar Stock
Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q2 2022 Results - Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q2 Earnings and Revenues Beat Estimates
Fulgent Genetics Reports Second Quarter 2022 Financial Results
2 No-Brainer Stocks to Buy Right Now for Less than $55
Fulgent Is Putting Its Cash Bonanza To Work
Source: https://incomestatements.info
Category: Stock Reports